肥厚型心肌病(Hypertrophic cardiomyopathy, HCM)是以左心室及室间隔不对称肥厚为基本特征的原发性心肌病, 其发病率约为0.2%, 是青少年和运动员心源性猝死的最常见原因。HCM的发病年龄、发病程度和猝死风险等临床表型具有多样性, 通常呈常染色体显性遗传。目前已报道的HCM相关突变超过900种, 主要定位在β肌球蛋白重链基因、肌球蛋白结合蛋白C基因、心脏肌钙蛋白T基因等13个心脏肌节蛋白基因; 另一方面, 越来越多的研究显示线粒体基因突变与HCM发生相关。文章在简单介绍HCM形态学特征及临床表型的基础上, 着重综述了HCM的致病分子机制及其最新研究进展。
Hypertrophic Cardiomyopathy (HCM) is a primary cardiac disorder characterized by asymmetric thickening of the septum and left ventricular wall. HCM affects 1 in 500 individuals in the general population, and it is the most common cause of sudden death in the young and athletes. The clinic phenotype of HCM is highly variable with respect to age at onset, degree of symptoms, and risk of sudden death. HCM is usually inherited as a Mendelian autosomal dominant trait. To date, over 900 mutations have been reported in HCM, which were mainly located in 13 genes encoding cardiac sarcomere protein, e.g., MYH7, MYBPC3, and TnT. In addition, more and more mitochondrial DNA mutations were reported to be associated with the pathogenesis of HCM. Based on the description of the clinical phenotype and morphological characteristics, this review focuses on the research in the molecular pathogenic mechanism of HCM and its recent advances.
[1] Brock R. Functional obstruction of the left ventricle (acquired aortic subvalvular stenosis). Guys Hosp Rep, 1957, 106(4): 221-238.
[2] Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J, 1958, 20(1): 1-8.
[3] Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes: Clinical, demographic, and pathological profiles. JAMA, 1996, 276(3): 199-204.
[4] Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Trans-plantation Committee; Quality of Care and Outcomes Re-search and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemi-ology and Prevention. Circulation, 2006, 113(14): 1807-1816.
[5] Hershberger RE, Cowan J, Morales A, Siegfried JD. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail, 2009, 2(3): 253-261.
[6] Geisterfer-Lowrance AAT, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, Seidman JG. A molecular basis for familial hypertrophic cardiomyopathy: a β cardiac myosin heavy chain gene missense mutation. Cell, 1990, 62(5): 999-1006.
[7] Alcalai R, Seidman JG, Seidman CE. Genetic basis of hyper-trophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electr, 2008, 19(1): 104-110.
[8] Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation, 2003, 107(17): 2227-2232.
[9] Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, Butany J. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol, 2009, 62(3): 226-235.
[10] Zeviani M, Gellera C, Antozzi C, Rimoldi M, Morandi L, Villani F, Tiranti V, DiDonato S. Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNALeu(UUR). Lancet, 1991, 338(8760): 143-147.
[11] Raha S, Merante F, Shoubridge E, Myint AT, Tein I, Benson L, Johns T, Robinson BH. Repopulation of rho0 cells with mitochondria from a patient with a mitochondrial DNA point mutation in tRNA(Gly) results in respiratory chain dysfunc-tion. Hum Mutat, 1999, 13(3): 245-254.
[12] Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA, 2002, 287(10): 1308-1320.
[13] Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular genetics of familial hypertrophic cardio-myopathy (FHC). J Hum Genet, 2003, 48(2): 55-64.
[14] Poliac LC, Barron ME, Maron BJ. Hypertrophic cardio-myopathy. Anesthesiology, 2006, 104(1): 183-192.
[15] Tam SK, Gu W, Mahdavi V, Nadal-Ginard B. Cardiac myo-cyte terminal differentiation. Potential for cardiac regeneration. Ann N Y Acad Sci, 1995, 752: 72-79.
[16] Marian AJ. Contemporary treatment of hypertrophic cardio-myopathy. Tex Heart Inst J, 2009, 36(3): 194-204.
[17] Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest, 2010, 40(4): 360-369.
[18] 齐建光, 杜军保. 线粒体心肌病临床诊断和基因研究进展. 中国实用儿科杂志, 2005, 20(6): 374-376.
[19] Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol, 2001, 33(4): 655-670.
[20] Marian AJ. Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol, 2008, 23(3): 199-205.
[21] 李文, 马沛然, 汪翼, 韩秀珍,
